IDWeek: Annual Meeting 2025 Highlights

IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

IDWeek 2025 took place in Atlanta, Georgia, between 19-22 October 2025.

GlobalData's infectious diseases team attended industry-sponsored and scientific sessions where key therapies were featured, the contents of which were analyzed to create this IDWeek 2025 Highlights report.

Scope

Indications, companies, and therapies discussed in the report are as follows -

• Respiratory syncytial virus (RSV)
• Moderna - mRNA-1345 (mRESVIA)
• Enanta Pharmaceuticals - EDP-323
• COVID-19
• Moderna - mRNA-1273.815 (Spikevax XBB.1.5)
• Invivyd - Pemivibart (Pemgarda)
• Complicated urinary tract infections (cUTIs)/acute pyelonephritis
• GSK and Spero Therapeutics - Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr)
• HIV
• ST Pharm - Pirmitegravir (STP0404)
• Nontuberculous mycobacteria (NTM)
• Paratek Pharmaceuticals - Omadacycline (Nuzyra)
• Gonorrhea
• Innoviva Specialty Therapeutics - Zoliflodacin
• Complicated Staphylococcus aureus bacteremia (SAB)
• Armata Pharmaceuticals - AP-SA02
• Fungal Infections
• Elion Therapeutics - EL219
• Herpes simplex virus (HSV)
• AiCuris - Pritelivir

Reasons to Buy

This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as HIV, COVID-19, RSV, NTM, UTIs, and more.

Inside the report you'll find -

• Emerging trends in prophylactic or therapeutic strategies for the management of viral, bacterial, and fungal infections
• Insights into the disease areas that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations